Nuclear thyroid hormone (T 3 ) receptors (TR) play a critical role in mediating the effects of T 3 on development, differentiation and normal physiology of many organs. The heart is a major target organ of T 3 , and recent studies in knockout mice demonstrated distinct effects of the different TR isoforms on cardiac function, but the specific actions of TR isoforms and their specific localization in the heart remain unclear. We therefore studied the expression of TR 1, TR 2 and TR 1 isoforms in the mouse heart at different stages of development, using monoclonal antibodies against TR 1, TR 2 and TR 1. In order to identify distinct components of the embryonic heart, in situ hybridization for cardiac-specific markers was used with the expression pattern of sarcoplasmic reticulum calcium-ATPase 2a as a marker of myocardial structures, while the pattern of expression of connexin40 was used to indicate the developing chamber myocardium and peripheral ventricular conduction system. Here we show that in the ventricles of the adult heart the TR 1 isoform is confined to the cells that form the peripheral ventricular conduction system. TR 1, on the other hand, is present in working myocardium as well as in the peripheral ventricular conduction system. In the atria and in the proximal conduction system (sinoatrial node, atrioventricular node), TR 1 and TR 1 isoforms are coexpressed. We also found the heterogeneous expression of the TR 1, TR 2 and TR 1 isoforms in the developing mouse heart, which, in the case of the TR 1 isoform, gradually revealed a dynamic expression pattern. It was present in all cardiomyocytes at the early stages of cardiogenesis, but from embryonic day 11·5 and into adulthood, TR 1 demonstrated a gradual confinement to the peripheral ventricular conduction system (PVCS), suggesting a specific role of this isoform in the formation of PVCS. Detailed knowledge of the distribution of TR 1 and TR 1 in the heart is of importance for understanding not only their mechanism of action in the heart but also the design and (clinical) use of TR isoform-specific agonists and antagonists.